Protagonist Therapeutics, Inc (PTGX) stock
PTGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 12/30199% above fair value
$124.67−0.16 (-0.13%)
Close on Nov 17, 2026Market cap $8.07BP/E 121.0Yield –
Protagonist Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Protagonist Therapeutics's ebitda for the twelve months ending Jun 30, 2026 was $59.88M, up 140.8% year over year. For fiscal 2025 it was -$156.85M, down 161.8% from the year before. The highest annual figure on record is $253.67M in fiscal 2024.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$156.85M | -161.8% |
| FY2024 | Dec 31, 2024 | $253.67M | – |
| FY2023 | Dec 31, 2023 | -$92.68M | – |
| FY2022 | Dec 31, 2022 | -$130.34M | – |
| FY2021 | Dec 31, 2021 | -$125.03M | – |
| FY2020 | Dec 31, 2020 | -$63.57M | – |
| FY2019 | Dec 31, 2019 | -$79.79M | – |
| FY2018 | Dec 31, 2018 | -$41.74M | – |
| FY2017 | Dec 31, 2017 | -$37.49M | – |
| FY2016 | Dec 31, 2016 | -$32.35M | – |
| FY2015 | Dec 31, 2015 | -$14.55M | – |
| FY2014 | Dec 31, 2014 | -$9.06M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $159.16M | – |
| Q1 FY2026 | Mar 31, 2026 | -$3.24M | – |
| Q4 FY2025 | Dec 31, 2025 | -$49.98M | -139.4% |
| Q3 FY2025 | Sep 30, 2025 | -$46.06M | – |
| Q2 FY2025 | Jun 30, 2025 | -$41.74M | – |
| Q1 FY2025 | Mar 31, 2025 | -$19.07M | -109.2% |
| Q4 FY2024 | Dec 31, 2024 | $126.90M | +444.7% |
| Q3 FY2024 | Sep 30, 2024 | -$41.22M | – |
| Q2 FY2024 | Jun 30, 2024 | -$38.55M | – |
| Q1 FY2024 | Mar 31, 2024 | $206.55M | – |
| Q4 FY2023 | Dec 31, 2023 | $23.30M | – |
| Q3 FY2023 | Sep 30, 2023 | -$38.08M | – |
| Q2 FY2023 | Jun 30, 2023 | -$42.12M | – |
| Q1 FY2023 | Mar 31, 2023 | -$35.77M | – |
| Q4 FY2022 | Dec 31, 2022 | -$36.26M | – |
| Q3 FY2022 | Sep 30, 2022 | -$32.03M | – |
| Q2 FY2022 | Jun 30, 2022 | -$41.18M | – |
| Q1 FY2022 | Mar 31, 2022 | -$20.86M | – |
| Q2 FY2021 | Jun 30, 2021 | -$30.70M | – |
| Q1 FY2021 | Mar 31, 2021 | -$23.84M | – |
| Q4 FY2020 | Dec 31, 2020 | -$18.48M | – |
| Q3 FY2020 | Sep 30, 2020 | -$7.59M | – |
| Q2 FY2020 | Jun 30, 2020 | -$18.02M | – |
| Q1 FY2020 | Mar 31, 2020 | -$19.48M | – |
| Q4 FY2019 | Dec 31, 2019 | -$17.07M | – |
| Q3 FY2019 | Sep 30, 2019 | -$16.97M | – |
| Q2 FY2019 | Jun 30, 2019 | -$31.23M | – |
| Q1 FY2019 | Mar 31, 2019 | -$14.52M | – |
| Q4 FY2018 | Dec 31, 2018 | -$15.28M | – |
| Q3 FY2018 | Sep 30, 2018 | -$9.24M | – |
| Q2 FY2018 | Jun 30, 2018 | -$9.07M | – |
| Q1 FY2018 | Mar 31, 2018 | -$8.15M | – |
| Q4 FY2017 | Dec 31, 2017 | -$3.40M | – |
| Q3 FY2017 | Sep 30, 2017 | -$4.87M | – |
| Q2 FY2017 | Jun 30, 2017 | -$15.04M | – |
| Q1 FY2017 | Mar 31, 2017 | -$14.19M | – |
| Q4 FY2016 | Dec 31, 2016 | -$11.32M | – |
| Q3 FY2016 | Sep 30, 2016 | -$7.06M | – |
See a number that looks wrong?